GlycoMimetics, Inc. (GLYC): Price and Financial Metrics
GLYC Stock Summary
- Glycomimetics Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 12.11% of US listed stocks.
- For GLYC, its debt to operating expenses ratio is greater than that reported by only 7.88% of US equities we're observing.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.09 for Glycomimetics Inc; that's greater than it is for merely 8.75% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Glycomimetics Inc are SRRK, CMRX, SGMO, DTIL, and ALPN.
- Visit GLYC's SEC page to see the company's official filings. To visit the company's web site, go to www.glycomimetics.com.
GLYC Stock Price Chart Interactive Chart >
GLYC Price/Volume Stats
| Current price | $2.53 | 52-week high | $5.19 |
| Prev. close | $2.61 | 52-week low | $2.38 |
| Day low | $2.47 | Volume | 366,339 |
| Day high | $2.64 | Avg. volume | 838,911 |
| 50-day MA | $3.20 | Dividend yield | N/A |
| 200-day MA | $3.57 | Market Cap | 130.39M |
GlycoMimetics, Inc. (GLYC) Company Bio
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. The company was founded in 2003 and is based in Rockville, Maryland.
Latest GLYC News From Around the Web
Below are the latest news stories about Glycomimetics Inc that investors may wish to consider to help them evaluate GLYC as an investment opportunity.
Positive Findings From Phase 1b Trial of GlycoMimetics’ GMI-1359 To Be Presented at AACR 2021 MeetingGlycoMimetics, Inc. (Nasdaq: GLYC) today announces that a Phase 1b trial of GMI-1359, being conducted at Duke University Cancer Center, showed evidence of on-target effects, immune-activation and cell mobilization in the initial two patients treated with the Company’s dual antagonist of E-selectin and CXCR4. Dorothy Sipkins, MD, PhD, Associate Research Professor in Pharmacology and Cancer Biology at Duke University School of Medicine, will present results from the proof-of-concept clinical study as well as a separate preclinical study supporting the positive biologic findings of the Phase 1b study. The presentation will be made at the American Association of Cancer Research (AACR) 2021 Annual Meeting, which is being held virtually on April 10-15 and May 17-21. GMI-1359 is GlycoMimetics’... |
GlycoMimetics to Present at AACR 2021 Meeting on Positive Therapeutic Effects of GMI-1757 in a Pancreatic Adenocarcinoma ModelGlycoMimetics, Inc. (Nasdaq: GLYC) today announces that an abstract presenting the results of a recent preclinical study on the therapeutic effects of GMI-1757, a new glycomimetic with dual antagonism to E-selectin and galectin-3, has been accepted for a poster presentation at the American Association of Cancer Research (AACR) 2021 Annual Meeting, to be held virtually on April 10-15 and May 17-21. |
KPTI, CENX, GMAB and TCRR among after-hours moversGainers: [[GLYC]] +3.5%. [[CBAY]] +2.6%. [[KPTI]] +2.6%. [[GMAB]] +2.5%. [[SYRS]] +2.4%.Losers: [[VECT]] -8.1%. [[TCRR]] -2.4%. [[JFIN]] -2.3%. [[CENX]] -2.2%. [[GURE]] -1.8%.... |
Penny Stocks to Buy Using Technical Analysis for April 2021While penny stocks are inherently risky, a knowledge of technical analysis can help you profit from these inexpensive investments. |
Apollomics, Inc Doses First Patient in Phase 1 Clinical Trial in China of GlycoMimetics’ Uproleselan for the Treatment of AMLROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics (Nasdaq: GLYC) today announced that Apollomics has dosed the first patient in China in a Phase 1 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML). In February of this year, Apollomics initiated two Phase 1 study sites in Greater China. “Dosing of the first patient in Greater China is a significant accomplishment for Apollomics. Equally important is the fact that A |
GLYC Price Returns
| 1-mo | -19.17% |
| 3-mo | -34.96% |
| 6-mo | -21.67% |
| 1-year | 1.20% |
| 3-year | -85.72% |
| 5-year | -58.73% |
| YTD | -32.71% |
| 2020 | -28.92% |
| 2019 | -44.14% |
| 2018 | -43.60% |
| 2017 | 175.25% |
| 2016 | 6.64% |
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...